Xcout Intel
MABION SA MABION
Mabion SA operates as a biotechnology company and Contract Development and Manufacturing Organization (CDMO) that provides services encompassing process development, analytics, and drug substance manufacturing. The company specializes in working with biologics such as biosimilars, antibodies, antibody-drug conjugates (ADCs), and recombinant therapeutic proteins to serve biopharmaceutical clients.
Subscribe to see MABION SA MABION’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MABION SA MABION at a glance
MABION SA MABION is a biotech company headquartered in United Kingdom. Xcout tracks 13 named people at MABION SA MABION, including Dr. Thomas Richter (CEO of BTI).
MABION SA MABION leadership
- Dr. Thomas RichterCEO of BTI
- Gregor KawaletzChief Executive Officer
- Detlef BehrensChief Business Affairs Officer
- Joaquín Santos BenitoChief Transformation Officer
- Jonas Skjødt MøllerEx-Head of Advance Technologies at Sartorius
- Dr. Firelli AlonsoEx-Executive Director at Pfizer
7 more named people on record for MABION SA MABION, with roles, board committees and tenure — see the full roster →
MABION SA MABION competitors
A few of MABION SA MABION's closest competitors — see the full list of competitors and alternatives →
Polpharma Biologics is a biotechnology company that develops and manufactures biosimilar medicines to improve patient access to biopharmaceuticals. Operating from Switzerland, the company manages a broad portfolio of biosimilars targeting major therapeutic areas and collaborates with global biopharmaceutical partners to bring these treatments from concept to commercial supply.
Samsung Biologics operates as a global contract development and manufacturing organization (CDMO) providing end-to-end biopharmaceutical services to pharmaceutical and biotech companies. The company offers a range of services including cell line development, process development, analytical testing, drug substance and drug product manufacturing, and advanced modalities like bioconjugation and mRNA.
AGC Biologics is a global contract development and manufacturing organization (CDMO) that provides services for protein-based biologics and advanced therapies, including mammalian and microbial production, viral vectors, cell therapy, plasmid DNA, and mRNA. The company supports biopharmaceutical developers by offering process development, analytical formulation, cGMP manufacturing, and fill-finish services to help bring life-changing treatments to market.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
Rentschler Biopharma SE is a contract development and manufacturing organization (CDMO). It is part of Dr. Rentschler Holding GmbH & Co. KG and its employees make up the majority of the 1300 workers employed by the parent organization.
Get MABION SA MABION's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MABION SA MABION in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access